Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.66 USD
Change Today +0.33 / 3.54%
Volume 242.3K
NVIV On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$9.26
Previous Close
$9.33
Day High
$9.69
Day Low
$9.26
52 Week High
04/17/15 - $19.68
52 Week Low
09/10/14 - $1.86
Market Cap
260.9M
Average Volume 10 Days
415.3K
EPS TTM
$-1.14
Shares Outstanding
27.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injury (SCI). The company is developing a Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold for the implantation at the site of injury within a spinal cord contusion; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Boston Children's Hospital and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

31 Employees
Last Reported Date: 03/11/15
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $532.3K
Chief Financial Officer
Total Annual Compensation: $369.1K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $171.1K
Chief Scientific Officer
Total Annual Compensation: $253.7K
Compensation as of Fiscal Year 2014.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Holdings Corp. Primary Exchange Listing has Changed to Nasdaq Global Market from Nasdaq Capital Market

InVivo Therapeutics Holdings Corp. primary exchange listing has changed to Nasdaq Global Market from Nasdaq Capital Market.

InVivo Therapeutics Holdings Corp. Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial

InVivo Therapeutics Holdings Corp. announced that a fourth patient has been enrolled in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute thoracic spinal cord injury at the UC Davis Medical Center in Sacramento, CA. The Investigational Device Exemption (IDE) pilot study has been approved by the FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. Following the pilot trial, InVivo expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).

InVivo Therapeutics Holdings Corp. Announces Auditor Changes

The Audit Committee of the Board of Directors of InVivo Therapeutics Holdings Corp. appointed McGladrey LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015. As a result, on August 7, 2015, the Committee dismissed Wolf & Company, P.C. as the Company's independent registered public accounting firm.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $9.66 USD +0.33

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 16.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.